1. [First outcomes, since being full member of Eurotransplant. A single center experience of cadaveric kidney transplantation].
- Author
-
Nemes B, Fedor R, Kanyári Z, Lőcsey L, Juhász F, Kovács DÁ, Zádori G, Győry F, P Szabó R, Zsom L, Szabó T, Illésy L, Szabó-Pap M, Kincses Z, Szabó L, Damjanovich L, Balla J, and Asztalos L
- Subjects
- Adult, Cadaver, Comorbidity, Europe, Female, Graft Rejection etiology, Graft Survival, Humans, Hungary epidemiology, Immunosuppression Therapy, Incidence, Kidney Failure, Chronic mortality, Kidney Failure, Chronic surgery, Kidney Transplantation adverse effects, Kidney Transplantation mortality, Living Donors statistics & numerical data, Male, Middle Aged, Postoperative Complications epidemiology, Postoperative Complications etiology, Retrospective Studies, Graft Rejection epidemiology, Kidney Transplantation methods, Kidney Transplantation statistics & numerical data
- Abstract
Introduction: The first renal transplantation was completed in 1991 at the University of Debrecen. In 2013 Hungary joined Eurotransplant., Aim: The authors retrospectively compared the trends., Method: Comparison between Period A (from January 1, 2008 to August 31, 2013) and Period B (from September 1, 2013 to October 22, 2015)., Results: The proportion of living transplants rose from 3.5% to 9.1 %. During period B over 25% of utilized donors were over 60 years of age. Recipients with body mass index above 30 kg/m(2) increased from 12% to 31%. Prevalence of diabetes among recipients rose twofold. Uretero-neocystostomy was used during period A (99%) while in period B end to side uretero-ureteral anastomosis has also gained popularity (68%). In 2013 the authors introduced routine use of induction treatment. Acute rejection rate decreased from 34% to 8%. The rate of surgical complications did not change. Acute bacterial infections decreased from 41% to 33%. Cumulative renal allograft 1, 3 and 5 year survival rates were 86.6%, 85% and 82.7% in group A vs. projected rates 88%, 84% and 84% in group B, respectively., Conclusions: Despite the growing proportion of expanded criteria donors, the authors were able to maintain a low incidence of delayed graft function and a favorable graft survival. Since 2013 the authors introduced treatments for acute humoral rejection according to international standards.
- Published
- 2016
- Full Text
- View/download PDF